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Abstract
Background: Low RNA yields from small tissue samples can limit the use of oligonucleotide
microarrays (Affymetrix GeneChips®). Methods using less cRNA for hybridization or amplifying the
cRNA have been reported to reduce the number of transcripts detected, but the effect on realistic
experiments designed to detect biological differences has not been analyzed. We systematically
explore the effects of using different starting amounts of RNA on the ability to detect differential
gene expression.
Results: The standard Affymetrix protocol can be used starting with only 2 micrograms of total
RNA, with results equivalent to the recommended 10 micrograms. Biological variability is much
greater than the technical variability introduced by this change. A simple amplification protocol
described here can be used for samples as small as 0.1 micrograms of total RNA. This amplification
protocol allows detection of a substantial fraction of the significant differences found using the
standard protocol, despite an increase in variability and the 5' truncation of the transcripts, which
prevents detection of a subset of genes.
Conclusions: Biological differences in a typical experiment are much greater than differences
resulting from technical manipulations in labeling and hybridization. The standard protocol works
well with 2 micrograms of RNA, and with minor modifications could allow the use of samples as
small as 1 micrograms. For smaller amounts of starting material, down to 0.1 micrograms RNA,
differential gene expression can still be detected using the single cycle amplification protocol.
Comparisons of groups of four arrays detect many more significant differences than comparisons
of three arrays.
Background
The ability to measure the expression of thousands of
genes at once using microarrays has opened new areas of
research, including global examination of the effects of
perturbations on cells or animals and the classification of
tumors by their pattern of gene expression. Microarrays
using cDNAs [1,2] and oligonucleotides [3–5] have both
proven valuable.
Commercially available oligonucleotide microarrays pro-
vide a standardized tool that allows assay of thousands of
mRNAs at one time. Affymetrix GeneChips® contain pairs
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of 25-nucleotide sequences (probe pairs) synthesized on
silica wafers; one of each pair exactly matches the se-
quence of interest and the other contains a single mis-
matching nucleotide in the center [6,7]. A single sequence
is queried by a group of 8 to 16 probe pairs that constitute
a probe set. RNA from the sample is converted to double-
stranded cDNA and then labeled by in vitro transcription
with biotinylated nucleotides. The biotinylated cRNA is
hybridized to the GeneChip®, unhybridized material is
washed off, and the signal is detected using fluorescein-la-
beled Streptavidin [8].
The standard Affymetrix protocol [8] uses as starting ma-
terial 10 µg of total RNA, from which biotinylated cRNA
is synthesized. This can limit the use of this system for
small samples from biopsies, laser capture microdissec-
tion or tissues from model organisms such as mice. Ma-
hadevappa and Warrington [9] examined the effect of
using less biotinylated cRNA in the hybridization. Hybrid-
ization reactions that contained the recommended 10 µg
of cRNA (from human endometrium adenocarcinoma
cells) detected 35% of the 1779 transcripts on the Gene-
Chip®. Reducing the amount of cRNA in the hybridization
to 5 µg reduced the fraction detected to 30%, and further
reducing the cRNA to 2.5 µg allowed detection of only
27% of the sequences [9]. Ohyama et al. [10] tested a
modified protocol for synthesizing biotinylated cRNA
from very small amounts of starting material. Total RNA
from laser capture microdissected human oral cancer tis-
sues was converted into cDNA and transcribed in vitro; the
resulting cRNA was converted into cDNA and transcribed
in vitro a second time to generate more cRNA; this cRNA
was again converted into cDNA and biotinylated cRNA
was synthesized by a third in vitro transcription. This pro-
cedure produced 10 µg of biotinylated cRNA from 0.1 µg
of starting total RNA. Hybridization with 10 µg of bioti-
nylated cRNA generated by this amplification protocol al-
lowed detection of 30% of the 7000 transcripts on the
HuGeneFL GeneChip®  [10]. In contrast, hybridization
with 10 µg of biotinylated cRNA generated by the stand-
ard protocol from total RNA extracted from similar tissues
resulted in detection of 35% of the transcripts being de-
tected [10].
Rather than focusing upon the number of transcripts de-
tected, the real test of a microarray protocol is the extent
to which it allows differences in expression levels to be re-
liably detected. The biological variability inherent in most
experimental models, including both genetic and envi-
ronmental differences between animals or even replicate
cell cultures, limits the detection of such differences. Ad-
ditional variability in the treatment and handling of the
models and in the RNA extraction typically occur outside
the microarray laboratory, and can be reduced (but not
eliminated) by careful experimental design. There is the
potential for introducing additional technical variability
during the synthesis of biotinylated cRNA. In evaluating a
new protocol or comparing existing protocols, measures
such as the yield of cRNA or the fraction of probe sets de-
tected can be useful, but the key measure is the extent to
which differences in gene expression can be detected in a
realistic experiment.
We have systematically explored the use of smaller
amounts of starting material (total RNA) in a model ex-
periment that retains the individual-to-individual biolog-
ical variation of a real experiment. This allowed us to
compare technical variability to the biological variability
in a typical experiment. We started with total RNA from
individual rats exposed to two different nutritional regi-
mens and used serial dilutions of the RNA to simulate ex-
perimental systems that provide smaller quantities of total
RNA. We used the Rat Genome RGU34A GeneChip® for
all of the experiments. Our first goal was to determine a
reasonable lower bound for total RNA that could success-
fully be used in the standard protocol. Second, we wanted
to test a modified version of the Ohyama amplification
procedure [10] that we thought would be faster, simpler
and less likely to skew results due to truncation of the la-
beled cRNA. We examined the variability and the ability
to detect significant changes between animals fed the 2
different dietary regimens when different amounts of
starting material and different protocols were used.
Results
Yields and quality of cRNA
The standard protocol uses 10 µg of total RNA to produce
biotinylated cRNA [8]. In our experiment, the average
yield of biotinylated cRNA was 97 µg (± 41 µg; mean ±
standard deviation) when we started with 10 µg of RNA
and used one-half of the double stranded cDNA product
in the in vitro transcription reaction. Starting with 2 µg of
total RNA, we obtained an average of 50 µg (± 20 µg;
standard deviation) of biotinylated cRNA after using all of
the double stranded cDNA product in the in vitro tran-
scription reaction. The 1 µg pooled samples produced an
average of 5.6 µg of biotinylated cRNA (yields ranged
from 2.4 µg to 7.7 µg). No difference in yield was ob-
served between the samples prepared with the ENZO and
Epicentre T7 polymerases. This lack of difference led us to
select the Epicentre Ampliscribe™ T7 High Yield Kit for the
extra in vitro transcription step to decrease expense.
The standard Affymetrix protocol uses 15 µg of biotinylat-
ed cRNA to make a 300 µl hybridization cocktail, of which
200 µl is injected into the chip for hybridization. The yield
of cRNA from both 10 µg and 2 µg of starting RNA
(above) were more than sufficient for this. Because yields
of cRNA starting from 1 µg total RNA were too low, we de-
cided to use an additional amplification step for RNABMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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samples less than 1 µg. Our modified protocol uses the in-
itial in vitro transcribed cRNA as starting material for a sec-
ond round of cDNA synthesis and in vitro transcription
(Methods). The cRNA yields from the 0.5 µg samples with
our protocol averaged 32 µg (± 13 µg), more than enough
for the standard hybridizations. The cRNA yields from the
0.1 µg samples using the same protocol averaged 10 µg
with a range from 5 to 21 µg, so some samples had too lit-
tle to prepare a hybridization mixture at the same concen-
tration. Therefore, the 0.1 µg samples were hybridized to
GeneChips® using 5 µg to 7.5 µg of cRNA to assess results
using these limited amounts.
Aliquots of the biotinylated cRNA samples were analyzed
by agarose gel electrophoresis to check the quality and
length. The cRNA for both the 10 µg and 2 µg samples
ranged from 200 to over 2,000 bases (before fragmenta-
tion). The cRNA from the 0.5 µg sample prepared by the
amplification protocol ranged from 200 to 850 bases, a
considerable decrease in maximum length. The 0.1 µg
samples were too faint to judge their size range.
Changes in sensitivity as measured by detection of probe 
sets
For a particular tissue or cell type, the percent present and
the scaling factors should be similar among all arrays in
the same experiment in the absence of variability intro-
duced by preparation, labeling, and handling of the indi-
vidual samples. Because we created groups of samples
diluted from the same individual RNA preparations, any
group differences reflect differences in labeling and han-
dling of the samples. We used the percent of probe sets
called present and the scaling factor (see Methods) for an
initial comparison among the groups (Table 1). The 2 µg
samples were essentially equivalent to the 10 µg samples
by these measures (Table 1). For the amplified samples
(0.5 µg and 0.1 µg starting material), the percent present
was decreased and the scaling factor increased compared
to the non-amplified samples. The percent present
dropped to 30.2% in the 0.5 µg group (78% of that detect-
ed in the 10 µg group) and even further, to 24.5%, for the
0.1 µg samples. Two other quality control measures, noise
and background, were similar across all 30 GeneChips®
(data not shown).
If the decrease in starting amount of RNA or the differenc-
es in protocol had no effect on the outcome, the signals
from all of the reduced RNA sample size groups would be
distributed similarly to the 10 µg group. SAS was used to
analyze the signals from each RNA sample size group.
Probe sets were separated by detection call (absent,
present and marginal) and analysis was performed sepa-
rately for each group (only 2% of the probe sets were
called marginal; these were omitted from Table 2). Signals
for the 2 µg samples are distributed similarly to the 10 µg
samples (Table 2). For the amplified samples the range of
signals is increased and the distribution is shifted toward
higher signal values. The decrease in percent of probe sets
called present on the GeneChips® from the amplified sam-
ples has the effect of lowering the average signal on the
chip, requiring a higher scaling factor (Table 1). This re-
sults in an inflation of the signal values for all of the probe
sets on these arrays.
To examine the effects of starting with smaller amounts of
RNA on the variability in detection of probe sets, we ex-
amined the number of probe sets that changed from
present to absent or from absent to present when compar-
ing the 10 µg sample to the smaller RNA samples from the
same animal (Table 3). The average number of probe sets
called present on the 10 µg chip and absent on the 2 µg
chip (P10 to A) and called absent on the 10 µg chip and
present on the 2 µg chip (A10 to P) changes were similar.
The bulk of these changes were for probe sets with lower
levels of expression (Table 3). This distribution is consist-
ent with the greater variability seen in probe sets with low
signals (see below); there is no significant loss of low-level
transcripts in the 2 µg samples.
Because the amplified samples (from 0.5 µg and 0.1 µg
starting material) have a decrease in the percent of probe
sets called present (Table 1), the number of probe sets
Table 1: Quality control measures as a function of starting material.
Amount of starting RNA
10 µg2   µg0 . 5   µg0 . 1   µg
% Present 38.6% 37.8% 30.2% 24.5%
Scaling Factor 14.1 14.3 33.4 89.0
3'/5' GAPDH 1 . 71 . 66 . 15 . 5
3'/5' β-actin 1 . 51 . 59 . 28 . 2
Data are averages of all arrays in each RNA sample size group. 3'/5' signal ratios are given for GAPDH and β-actin.BMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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called present in the 10 µg samples and absent in the am-
plified sample from the same animal must be greater than
the number called absent in the 10 µg sample and present
in the amplified samples (Table 3). Loss of signal is ex-
pected in low-level transcripts for the amplified samples
because of the decrease in starting material, but probe sets
present in the 10 µg and absent in the amplified samples
are not confined to those probe sets with low signals. For-
ty-three percent of the probes not detected in the ampli-
fied samples have a signal greater than 600 in the 10 µg
sample, and 5% have a signal of at least 3200. In compar-
ison, for the 2 µg samples, only 14% of the probe sets
present in the 10 µg sample and absent in the 2 µg sample
had signals greater than 600, and none had signals over
3200.
The probe sets changing from absent in the 10 µg samples
to present in the amplified samples (Table 3) were mostly
those with low signals in the 10 µg samples, reflecting the
greater noise found in probe sets with low signals (Figure
1).
Biological and technical variability
The Affymetrix MAS5 comparison analysis tool was used
to compare expression levels between pairs of Gene-
Chips®. This analysis directly compares two arrays at each
individual probe pair rather than merely comparing the
signal computed from all of the probe pairs for a probe set
[11]. Comparisons among the 10 µg samples from differ-
ent animals within each of the treatment groups showed
that the biological (between animal) plus random techni-
cal variability is considerable (Table 4, 10 vs. 10). There
was an average of over 700 apparent differences in expres-
sion level between pairs of GeneChips® within a single
treatment group, 12% of which were 2-fold or greater. The
number of increases and decreases were comparable, sug-
gesting random rather than systematic changes. Increases
and decreases were randomly distributed across probe sets
with different levels of expression. This can be visualized
as a scatter plot comparing two different 10 µg samples
both from the vitamin-deficient group (Figure 1a and 1b);
results are similar for a pair of control samples. There is
noticeable scatter from the expected diagonal, and the
scatter is greatly exacerbated at low signal levels. This
shows variability between animals within a single
Table 2: Expression levels for probe sets called absent and present by MAS5.
Absent Present Maximum 
Signal
25% 50% 75% 90% 25% 50% 75% 90%
10 µg 25 69 169 328 446 1047 3220 10497 117836
2 µg 27 71 170 337 443 1052 3272 10769 123626
0.5 µg 34 94 223 438 628 1406 4315 14321 234230
0.1 µg 48 134 301 521 888 1877 5582 18228 439116
For each starting amount of RNA, the signals corresponding to the 25th percentile (25%), 50th percentile (50%), 75th percentile (75%) and 90th per-
centile (90%) are shown, along with the maximum signal.
Table 3: Variability in the detection of probe sets.
Changes in Detection1
<3002 300–6002 >6002
P10 to A3 A10 to P4 P10 to A3 A10 to P4 P10 to A3 A10 to P4
2.0 µg 104 (58%) 131 (74%) 51 (28%) 35 (20%) 25 (14%) 1 2 (7%)
0.5 µg 241 (28%) 128 (74%) 245 (29%) 32 (18%) 365 (43%) 1 4 (8%)
0.1 µg 346 (28%) 52 (68%) 355 (29%) 15 (19%) 523 (43%) 10 (13%)
1Changes in Dectection are the average number of Present to Absent and Absent to Present changes per chip when comparing the 10 µg chip to 
the reduced RNA sample chip from the same animal. 2Number of changes found among those probe sets that had a signal less than 300, 300 to 600 
or greater than 600 (as noted) in the 10 µg chip. 3Present in 10 µg chip, absent in reduced RNA sample chip from the same animal. 4Absent in 10 
µg chip, present in reduced RNA sample chip from the same animal.BMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
Page 5 of 15
(page number not for citation purposes)
Figure 1
Log scale scatter plots of samples labeled by the standard protocol. Lines indicate a 2-fold difference. (a) Two 10 µg 
treated samples, all probe sets shown. (b) Same as figure 1a, but limited to the probe sets called present in Sample A (x-axis). 
(c) 2 µg vs. 10 µg from the same animal (Sample A in figures 1a and 1b). (d) Same as figure 1c, but limited to probe sets called 
present in the 10 µg sample.
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treatment group (plus the technical variability in handling
two samples, even with the same protocol). Figure 1b is
the same pair of GeneChips® but is restricted to probe sets
that were called present in the first sample (Sample A, x-
axis). Analysis of the signals for all of the 10 µg arrays
shows that 59% of the probe sets have signals below 300,
and that 89% of these are called absent. Removing the
probe sets called absent from further analyses removes
most of the variability seen in this low signal range. The
data in Table 4 were limited to probe sets that were called
present in the baseline sample for each comparison to
avoid the noise of low signal absent and marginal calls (cf.
Figure 1).
GeneChips® from the lower RNA sample size groups were
compared to the 10 µg chip from the same animal; these
comparisons represent technical variation only, because
the RNAs were dilutions from the same RNA preparations.
To compare variability introduced by the same labeling
protocol with different amounts of starting material, in
Figure 1c and 1d we compared a 2 µg sample to a 10 µg
sample from the same animal (sample A, x-axis in a and
b). As can be seen, the variation due to differences in
sample size plus the technical variability is less than the
between-animal variation shown in Figure 1a and 1b. The
2 µg arrays have an average of 134 decreases and 136
increases when compared to the 10 µg samples from the
same animals (Table 5, 2 vs. 10); this reflects technical var-
iability of samples prepared by the same protocol from
different amounts of starting material. Only 4% of these
changes had a magnitude of 2-fold or greater, for an aver-
age of 10 changes per chip. This variability was much
smaller than the biological variation seen between pairs of
arrays from different animals (10 µg arrays, Table 4).
There were a balanced number of increases and decreases.
The changes in the 2 µg samples appear random: different
probe sets change in different comparisons. Only 8 probe
sets changed consistently (in at least 5 of the 6
comparisons).
To examine variability introduced by the amplification
protocol, we compared a 0.5 µg sample to a 10 µg sample
Table 4: Changes in comparisons between animals within treatment.
Between animal comparisons
Increases Decreases ALL
Samples Total ≥ 2-fold Total ≥ 2-fold Total ≥ 2-fold
10 vs. 10 335 31 374 51 709 82
0.5 vs. 0.5 426 143 506 144 932 287
The average number of changes detected by MAS5 per comparison between 2 GeneChips® (among probe sets called present in the baseline sam-
ple). Comparisons were made between animals in the same treatment group for both the 10 µg and 0.5 µg sample size groups to measure technical 
plus biological variability. "Total" is the number of changes regardless of magnitude; "≥ 2-fold" is the number of probe sets with changes of 2-fold or 
more. "Marginal Increases" and "Marginal Decreases" are included.
Table 5: Changes in comparisons between RNA sample size groups.
Between sample size groups
Increases Decreases ALL
Samples Total ≥ 2-fold Total ≥ 2-fold Total ≥ 2-fold
2 vs. 10 136 3 134 7 270 10
0.5 vs. 10 528 436 1043 654 1571 1090
0.1 vs. 10 255 252 1119 647 1374 899
0.1 vs. 0.5 103 42 593 69 696 111
The average number of changes detected by MAS5 per comparison between 2 GeneChips® (among probe sets called present in the baseline sam-
ple). Comparisons were made between samples from the same animal in two different RNA sample size groups to measure technical variation. 
"Total" is the number of changes regardless of magnitude; "≥ 2-fold" is the number of probe sets with changes of 2-fold or more. "Marginal 
Increases" and "Marginal Decreases" are included.BMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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from the same animal (Figures 2a and 2b). This compari-
son includes both systematic and random variability in-
troduced by the amplification protocol used for the 0.5 µg
sample. There was much more variability between the 10
µg and 0.5 µg samples than between 10 µg and 2 µg sam-
ples or between 10 µg samples (compare Figures 1 and 2).
Only probe sets that were called present in the 10 µg sam-
ple have been plotted in Figure 2b; the variability is still
high. This remaining variability extends over a wider
range of signals than for the comparisons in Figure 1.
More of the probe sets decreased in signal than increased
in signal. Many more of these changes are at least 2-fold.
The comparison of 0.1 µg to 10 µg data (not shown) is
very similar to the 0.5 µg to 10 µg comparison.
The number of changes observed from the comparison
analysis of the amplified samples to the 10 µg samples is
significantly higher than for the 2 µg samples, and there
are many more decreases than increases (Table 5, 0.5 vs.
10 and 0.1 vs. 10). The number of decreases exceeds 1000
per chip for both amplified groups. For the amplified
samples, nearly 2/3 of the changes are 2-fold or greater
(Table 5), another indication of the increased variability
also seen in Figures 2a and 2b. The changes for the ampli-
fied samples were spread evenly across the range of sig-
nals, except there were fewer increases seen in the low-
level transcripts of the 0.1 µg samples than for the 0.5 µg
samples, reflecting the loss of more low-level transcripts
in the 0.1 µg samples. Decreases in the amplified samples
were more consistent, with 727 and 794 probe sets that
decreased in at least 7 of the 8 samples for the 0.5 µg and
0.1 µg groups, respectively. Of the 727 probe sets that con-
sistently changed in the 0.5 µg samples, 712 decreased in
at least 6 of the 0.1 µg samples. This indicates that a group
of probe sets is being systematically affected in both of the
amplified groups (see below). A percentage of these de-
creases actually result in loss of detection of probe sets,
33% for the 0.5µg and 43% for the 0.1 µg samples.
To measure the level of variability within an amplified
group, the 0.5 µg arrays within a treatment group were
compared (Table 4, 0.5 vs. 0.5). The number of changes
within the 0.5 µg arrays was greater than within the 10 µg
arrays, 932 per chip compared to 709 for the 10 µg. Not
only were there more changes, a larger percentage of the
changes were 2-fold or greater, 30% vs. 12% for the 10 µg
samples. This indicates that additional noise was intro-
duced by the amplification.
The 0.1 µg and 0.5 µg samples from the same animal were
similar to each other (Figures 2c and 2d, Table 5). Only
16% of the differences between the 0.1 µg and 0.5 µg
groups were ≥ fold, compared to 65% that were ≥ 2 fold
when comparing the amplified samples to 10 µg samples.
The variation between the amplified groups (0.1 µg and
0.5 µg) is greater than the variation between the non-am-
plified groups (2 µg and 10 µg), and decreases outnumber
increases because of the greater loss of signal in the 0.1 µg
samples.
Amplification truncates the 5' ends of the RNA
A likely cause for the consistent decreases of particular
probe sets in the amplified samples, not related to low sig-
nal level, is the loss of the 5' end of the transcript. Synthe-
sis of cDNA from the cRNA initially prepared is expected
to lead to some truncation of the 5' ends of the original
mRNA, due to the requirement for priming during synthe-
sis of the second strand. Indeed, the cRNA prepared by
amplification from the 0.5µg samples was noticeably
shorter than that prepared by the standard protocol, as de-
tected by agarose gel electrophoresis (above). Another
way to detect such potential shortening of the probe sets
is to compare the signals from the Affymetrix control
probe sets. There are 3 probe sets each for GAPDH and β-
actin, designated 3', Middle and 5' based on their relative
distance from the 3' end of the transcript. The average 3'/
5' ratio for both 10 µg and 2 µg samples was 1.7 or below
(Table 1), representing good samples http://www.affyme-
trix.com. The 3'/5' ratios of the amplified samples all ex-
ceeded 3 and were as high as 14, with the average near 6
for GAPDH and 8.5 for β-actin (Table 1). These ratios in-
dicate a differential loss of the 5' ends of the transcripts for
the amplified samples (see below).
Examination of the Affymetrix comparison analyses for
the GAPDH and β-actin probe sets gives an even better
picture of the 5' loss. None of the comparisons of the 2 µg
samples to the 10 µg samples from the same animals
showed a significant change in signal for these probe sets.
All 8 of the 0.5 µg and 0.1 µg samples had significant de-
creases as compared to the 10 µg sample from the same
animal, the magnitude of which increases as the distance
of the probe sequence from the 3' end of the transcript in-
creases (Table 6). The amplified samples both show simi-
lar progressive loss of the more 5' sequences. For example,
both amplified samples have an average of 33% of the
GAPDH 3' signal (mean log2 ratio -1.6), but only 11% as
much GAPDH 5' signal (log2 ratio-3.1).
To determine if truncation of the 5' ends of the RNA may
be a significant problem for many of the sequences on the
GeneChip®, the distance of the target sequence (from
which probe sets were designed) from the 3' end of the
transcripts was determined for as many probe sets as
possible by BLASTing the target sequence against the nr
database (Figure 3). We then compared the percent of
probe sets that decreased in signal at different 3' distances.
The differences between the 2 µg and 10 µg samples were
evenly distributed across the 3' distances (Figure 4), rein-
forcing the idea that these are random differences. In con-BMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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Figure 2
Log scale scatter plot of amplified samples. Lines indicate a 2-fold difference. (a) 0.5 µg sample vs. 10 µg sample from the 
same animal as in figure 1c. (b) Same as a, but limited to probe sets called present in the 10 µg sample. (c) 0.1 µg vs. 5 µg from 
the same animal as in figures 2a and 2b. (d) Same as figure 2c, but limited to probe sets called present in the 0.5 µg sample.
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trast, the amplified samples (0.1 µg and 0. 5 µg) show a
marked increase in the percent of probe sets that were de-
creased as the target sequence is moved farther from the 3'
end (Figure 4).
Both sets of amplified samples were affected in the same
manner by this 5' truncation. The decreases seen when
comparing the 0.1 µg to the 0.5 µg samples were not asso-
ciated with distance from the 3' end and were not consist-
ent for particular probe sets (only 26 probe sets decreased
in at least 7 of the 8 samples). This indicates that the trun-
cation is a result of the single cycle of amplification, rather
than the amount of starting material.
Ability to detect differences in expression between treat-
ment groups
The main goal in an experiment comparing two treatment
groups is to find genes whose expression differs signifi-
cantly. To assess whether the lower starting amounts of to-
tal RNA can be used successfully, a comparison of results
from standard t-tests was performed. Based upon the data
in Figure 1, we filter out those probe sets that are not de-
tected in at least one of the treatment groups to be com-
pared before performing statistical comparisons. To be
conservative, we only eliminated probe sets that are not
called "present" on at least half of the GeneChips® in ei-
ther of the treatment groups (rather than demand that a
probe set be present in all of the GeneChips® in a set; oth-
ers can choose different fractions), and call this a
Figure 3
Distance of the target sequence from the 3' end of the transcript. The target sequence from which the probe sets are 
designed is aligned to the transcript. The distance in bases from the 3' end is calculated by subtracting the position of the 5' end 
of the alignment from the length of the transcript.
Table 6: Amplified samples show differential loss of 5' sequences.
Mean log2ratio Target range
Probe set 0.1 µg0 . 5   µg( n t  f r o m  3 ' )
GAPDH 5' -3.1 -3.1 883–1153
GAPDH M -2.6 -2.7 541–835
GAPDH 3' -1.6 -1.6 210–492
β-actin 5' -3.2 -3.7 798–1116
β-actin M -2.5 -2.6 432–726
β-actin 3' -1.0 -1.3 0–390
Average log2 ratios of expression in the amplified samples to that in the control sample (that started with 10 µg RNA) from the same animal. Target 
range is the position of the target sequence from the 3' end of the transcript.
 3'
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"detection filter." This does not eliminate probe sets that
are either turned on or off, because these would be present
in one of the two treatment groups.
Table 7 gives the number of probe sets that met our crite-
ria for significance: they passed the "detection filter" and
were significant at p ≤ 0.01 for the t-test or at the appro-
priate level for the Wilcoxon rank sum test (non-paramet-
ric) [13]; both tests give generally parallel results. Even
though both the 0.5 µg and 0.1 µg comparisons are 4 × 4
comparisons, there is a 50% drop in the number of signif-
icant probe sets as compared to the 10 µg samples. Only
part of this drop can be attributed to the decrease in the
percent of probe sets that met the "detection filter" for
these samples (Table 7); the extra noise introduced by the
amplification, as seen in the 0.5 µg group (cf. Figure 2, Ta-
bles 4 and 5), contributes substantially, since the t-test is
Figure 4
Reduction in signal as a function of the distance from the 3' end. Affymetrix comparison analysis was used to compare 
the reduced RNA samples to the 10 µg sample from the same animal. This plot shows the percentage of probe sets called 
"decreased" as a function of distance from the 3' end of the transcript. Analysis was limited to probe sets called present in the 
10 µg sample.
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sensitive to increases in standard deviations of the two
groups being tested.
Because of the loss of two of the 2 µg arrays, the table also
contains data for the subset of six that match the six re-
maining 2 µg arrays. Note the sharp decline in the number
of probe sets meeting the p ≤ 0.01 significance criteria (t-
test) when the number of samples in the 10 µg class is re-
duced from a 4 × 4 comparison to a 3 × 3 comparison (Ta-
ble 7); this attests to the additional power gained by using
the additional array. The best (lowest) p-value that can be
achieved in the Wilcoxon test with four samples for each
treatment group is 0.0143; for three samples per group it
is 0.05 [13]. The 2 µg samples also produced a similar
number of significant probe sets for the Wilcoxon with a
0.05 p-value as the 10 µg samples with the same number
of arrays, 585 for the 2 µg samples and 620 for the
corresponding 10 µg samples. These numbers can be com-
pared to the 869 found in the complete set of 10 µg sam-
ples (sample size of 4) with a p-value of 0.0571 for the
Wilcoxon.
As expected, probe sets with low expression level (low sig-
nal) were less reproducible in comparisons between the
different sample groups, as were probe sets with very low
fold-changes. Reproducibility for the 2 µg samples was
best for probe sets with a fold change ≥ 1.7 (log2 ratio ≥
0.75). For the amplified samples, good reproducibility
was achieved for probe sets with fold changes ≥ 2 (log2 ra-
tio ≥ 1). Calculated fold changes for the concordant probe
sets were reasonably stable across the different groups.
Estimate of technical false positive rate
The 2 µg and 10 µg groups were from the same original
RNA extractions and were labeled by the same protocol.
Because they were so comparable in all of our measures,
these 2 groups were used to estimate the number of false
positives due to technical variability to be expected using
our standard t-tests. The three 2 µg samples from the nor-
mal diet animals were compared to the three 10 µg sam-
ples from the same animals using the t-test, and the three
2 µg samples from the diet deficient animals were similar-
ly compared to the 10 µg samples from the same animals.
Since both of these comparisons are between samples
from the same set of similarly treated animals, one should
expect no changes. Therefore, any probe sets that were
found to be significantly different between the 2 µg and
10 µg samples from the same animals would be false pos-
itives. For each comparison, normal and deficient, 14
probe sets were found to be significantly different be-
tween the 2 µg and 10 µg samples, which is a false positive
rate of 0.4% of the probe sets that met the "detection fil-
ter." Of these 28, only 3 of the normal group and 4 of the
deficient group had a fold-change greater than 1.5 and
only one in each group had a fold-change that exceeded 2.
Fold-changes larger than 1.5 were seen only in probe sets
with average signals < 900. Those probe sets with signals
over 900 had smaller fold changes, most less than 1.3.
In comparison, for those probe sets that did not meet the
"detection filter", the false positive rate was approximately
1% at a p-value of 0.01. This set of false positives was
equally balanced between increases and decreases (53 in-
creases and 58 decreases in the two treatment groups), in-
dicating random noise and not an effect of using 2 µg
instead of 10 µg of RNA. The fold changes ranged from 1.2
to 12.5. The large fold changes result from very small de-
nominators used in the fold change calculations for these
probe sets.
Discussion
This experiment demonstrated that technical variability is
much smaller than biological variation when using the
standard protocol. The number of differences between
samples from the same animal that resulted from using
the lower amount of starting material was much smaller
than the biological variation between animals treated the
same and labeled by the standard protocol. The standard
Table 7: Number of significant probe sets for different groups of samples.
Significant Difference
Group Detection1 t-test2 Wilcoxon3
10 µg(4)* 3765 150 340
0.5 µg (4) 3090 75 175
0.1 µg(4) 2461 80 193
10 µg(3) 3662 86 NA
2 µg (3) 3666 83 NA
The number significant is the number of probe sets significantly different between vitamin sufficient and -deficient animals among those that are 
present in at least half of the arrays in at least one of the groups, 1number of probe sets that passed the detection filter, 2p-value ≤ 0.01 (t-test); 3 p-
value ≤ 0.0143 for Wilcoxon test; *Number in parentheses is the number of GeneChips® in each treatment group for the comparison;BMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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protocol worked well with samples as small as 2 µg, pro-
ducing results very similar to those of the 10 µg sample
from the same animal. Although in this experiment, start-
ing with less than 1 µg of total RNA did not produce
enough biotinylated cRNA for hybridization under the
normal protocol, a minor change (using vacuum evapora-
tion to concentrate samples before cRNA synthesis, and
mixing the minimum 200 µl hybridization volume)
should allow use of 1 µg samples with the standard
protocol. This extends the range of samples that can read-
ily be analyzed on Affymetrix GeneChips® using the stand-
ard protocol.
We have demonstrated here that a single cycle of amplifi-
cation sufficed to produce cRNA from samples as low as
0.1 µg of total RNA. The amplification protocol uses the
cRNA from the initial protocol as starting material for a
second round of cDNA synthesis and in vitro transcrip-
tion. We hypothesized that each round of cDNA synthesis
would lead to some truncation of the molecules, due both
to the possibility of priming the second strand from an in-
ternal site and to cleavage of the relatively labile RNA. For
this reason, we limited our amplification to a single
round, rather than using two cycles as had previously been
reported [10]. The hypothesized shortening was observed:
the cRNA extended to about 850 nt, compared with about
2000 nt for the standard protocol. This shortening was
also demonstrated by differential loss of signal from
probe sets further away from the 3' end of the RNA, as
shown with the Affymetrix control probe sets (Tables 1
and 6), and by the progressive loss in probe sets detected
as a function of their distance from the 3' end (Figure 4).
The amplification systematically affected over 700 probe
sets in at least 7 of 8 samples for both the 0.1 µg and 0.5
µg groups. Indeed, of the probe sets with consistent de-
creases across the 0.1 µg and 0.5 µg samples about 90%
have target distances greater than 400 nucleotides from
the 3' end of the measured transcript, with 26–28% in the
400–600 range and 60–62% over 600. Because the effect
of the loss of the 5' end is systematic, it renders a group of
probe sets designed from sequences further from the 3'
end undetectable. Therefore, we recommend using the
standard protocol instead of using the amplification strat-
egy for samples down to 1 µg of total RNA, and our
simplified amplification protocol for smaller samples, at
least down to 0.1 µg. This extends the range of samples
that can be usefully analyzed by oligonucleotide microar-
rays. This experiment used the Affymetrix RGU34A Gene-
Chip®, which was designed using version 34 of Uni Gene
for the rat, November 1998 For newer arrays such as the
new human U133 GeneChip®, designed using better se-
quence information and improved probe designs (Af-
fymetrix technical report Array Design for the GeneChip®
Human Genome 133 Set), we expect that the problem
with loss of the 5' end of the transcript. will be lessened,
but not eliminated, because the targets are more likely to
be near the real 3' ends of the mRNAs The truncation that
results from amplifying samples means that the same pro-
tocol should be used for all samples in a given study.
New protocols that increase the production of cDNA
[14,15] using primers attached to the 5' end of the tran-
script could increase cDNA yields from small amounts of
RNA But Iscove [14] states "only a few hundred bases of
extreme 3' sequence" are amplified by their method This
procedure would be expected to greatly exacerbate the loss
of signal due to shortened transcripts.
There was additional variation in the amplified samples
(Table 5) that is probably due to the extra steps required
in the protocol. This extra noise is partially responsible for
the decrease in the number of probe sets that differ at a p-
value ≤ 0.01. This, coupled with the decrease in the per-
cent of probe sets present, reduces the ability to find tran-
scripts that differ significantly in expression when using
the amplification protocol. The problem is exacerbated
for transcripts with small differences in expression (low
fold changes). Fold changes ≥ 2 were much more likely to
be identified in the amplified samples. It may be especial-
ly helpful to increase the number of arrays used in these
amplification experiments to get more power to detect
changes
Our experiment also provided a false positive estimate of
technical variability for the t-test with 14 found in each
treatment group when comparing the 10 µg samples to
the 2 µg samples (0.4% of the present probe sets.). These
false positives came disproportionately from the genes ex-
pressed at lower levels. Genes expressed at these low levels
often show high fold-changes because the denominator is
so low (often near background), this points out the dan-
ger in emphasizing high fold-changes, rather than repro-
ducible changes. Therefore, for genes expressed at lower
levels, it might be reasonable to use a more restrictive p-
value, none of the false positives had a p-value less than
0.001. Restricting probe sets to those minimally present
(our "detection filter") dramatically decreases the number
of false positives, from an average of 56 down to 14, re-
stricting analysis to genes called present in a higher frac-
tion of the arrays from one of the comparison groups
could further reduce false positives, but at the cost of miss-
ing some true positives. The tradeoff can be chosen by an
investigator based upon the relative cost of false positives
and value of detecting differences in genes expressed at
low levels.
The statistical power to detect differences was much re-
duced when 3 samples per group were analyzed instead of
4. The 2 µg samples and the matched 10 µg samples were
able to detect 83–86 differences at p ≤ 0.01 as comparedBMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
Page 13 of 15
(page number not for citation purposes)
to 150 differences when using all of the 10 µg samples.
This decrease was expected, but illustrates that a 25% de-
crease in expense may result in a much greater loss of
information.
Conclusions
This experiment explored the effects of using less than the
standard 10 µg of total RNA for an Affymetnx GeneChip®
experiment, and examined how biological and technical
variation affect the ability to detect biological differences
in a typical experiment comparing gene expression in two
conditions. The overall conclusions are that (1) small
amounts of RNA can be used effectively in the standard
protocol, (2) even very small amounts of RNA (0.1 µg)
can be used with our simplified amplification protocol to
detect differential gene expression, (3) biological varia-
tion is larger than technical variation, (4) very low-level
signals are prone to false positives and to less reliable fold-
changes, false positives can be reduced by filtering out
probe sets not reliably detected before statistical compari-
sons, and (5) using 4 independent biological samples is
much better than using 3 samples in allowing detection of
consistent changes and reducing false positives.
Methods
Labeling test
Total RNA was extracted from the livers of 4 rats fed a nor-
mal diet (untreated) and 4 fed a vitamin-deficient diet
(treated) using the RNeasy® kit (Qiagen Inc, Valencia,
CA). The RNA was resuspended and re-extracted using the
same protocol, to reduce DNA contamination. For the la-
beling test, two pools were created, one treated and one
untreated, by mixing equal aliquots from each of the 4
RNA samples. The final concentration was adjusted to 1
µg/2 µl, and each pool was divided into 4 aliquots of 1 µg
each. These pooled samples were used to determine the
average cRNA yield from 1 µg of total RNA and to com-
pare the yields of the T7 polymerases from two different
in vitro transcription kits. Biotinylated cRNA was prepared
using the standard Affymetrix protocol [8] except that the
Epicentre AmpliScribe™ T7 polymerase (Epicentre, Madi-
son, WI) was substituted for the ENZO T7 polymerase (Bi-
oArray, High Yield RNA Transcript Labeling Kit, ENZO
Diagnostics, Inc., Farmingdale, NY) for 2 of the treated
and 2 of the untreated pooled samples. The yield of cRNA
was estimated from absorbance at 260 nm, using an Am-
ersham Pharmacia Biotech Ultrospec 3100 pro spectro-
photometer. This part of the experiment was the only time
RNAs from different animals were pooled, the cRNAs
from these pooled samples were not hybridized to arrays.
Labeling for microarrays
Aliquots of each of the original 8 samples of total RNA
(one from each rat) were treated as individual samples for
all hybridization experiments. Each sample was serially
diluted to yield 10 µl samples containing 10 µg, 2 µg, 0.5
µg and 0.1 µg total RNA (32 samples). For the 10 µg and
2 µg samples, cRNA was prepared using the standard Af-
fymetrix protocol [8]. We made slight modifications for
the 2 µg samples to increase the concentration by decreas-
ing added water where that was possible. Because the
cRNA yield from the 1 µg pooled sample test was low, we
decided to amplify the smaller samples. The 0.5 µg and
0.1 µg samples were amplified by a modification of the
protocol of Ohyama et al. [10], using only a single round
of amplification. In short, double-stranded cDNA was
synthesized from the total RNA using the SuperScript II kit
from Invitrogen and the Affymetrix T7-(dT)24  primer,
which contains a T7 promoter attached to a poly-dT se-
quence 5'-GGCCAGTGAATTGTAATACGACTCACTATAG-
GGAGGCGG-(dT)24-3'. The Epicentre AmpliScribe T7
High Yield Transcription kit was used to produce unla-
beled cRNA by in vitro transcription with unbiotinylated
NTPs. This in vitro transcription step was followed by a
second round of double-stranded cDNA synthesis, and fi-
nally by in vitro transcription using the T7 RNA polymer-
ase with the Enzo BioArray, High Yield RNA Transcript
Labeling Kit with biotinylated NTPs in the usual manner.
Yields of cDNA and cRNA were measured using an Amer-
sham Pharmacia Biotech Ultrospec 3100 pro spectropho-
tometer in order to adjust concentrations for subsequent
steps. Measurements of the amplified samples were made
after the second round of cDNA synthesis and in vitro tran-
scription, to limit the loss of sample. After the final round
of cRNA synthesis, aliquots of biotinylated cRNA from
each sample were electrophoresed on 1% agarose gels in
TBE buffer to check them for quality and length, the buffer
and gel both contained a 500 ng/ml concentration of
ethidium bromide. The Invitrogen 1 Kb Plus DNA ladder
was used to provide a relative measure of length.
Since it was not feasible to label this many samples at one
time, a balanced experimental design was used processing
groups of 10 µg and 2 µg samples for the same animal to-
gether and always labeling an equal number of normal
and vitamin-deficient samples at one time. For the ampli-
fication protocol, 0.5 µg and 0.1 µg samples from the
same animal were processed together for each step, again
with balanced numbers of normal and vitamin deficient
samples processed together.
Array hybridization
Each sample was hybridized to a separate Affymetrix
RGU34A GeneChip®. For most samples, hybridization
cocktails of 300 µl contained 15 µg of fragmented cRNA,
200 µl of the cocktail were injected into the GeneChip® for
hybridization. One 2 µg sample had a lower yield so a 200
µl hybridization cocktail containing 10 µg of cRNA was
made, to keep the concentration fixed. For the 0.1 µg
samples, the cRNA yield was less than 15 µg so 5–7 5 µgBMC Genomics 2003, 4 http://www.biomedcentral.com/1471-2164/4/4
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of cRNA was used for the hybridization cocktail. Data
from two of the 2 µg GeneChips® (1 from each treatment
group) and their hybridization cocktail were unusable
due to a bad lot of BSA (used as a blocking factor during
hybridization). The analyses for the 2 µg group were
completed using the remaining 6 GeneChips®. For some
comparisons with this group, only the corresponding 6
GeneChips® from the 10 µg samples were used.
Scanning and analysis
Each GeneChip® was scanned and analyzed using Affyme-
trix Microarray Analysis Suite (MAS) version 5.0 [11].
Each sample was scaled to a target intensity of 1000 using
the "all probe sets" scaling option, this option scales the
trimmed mean target intensity to the specified value [11].
The Affymetrix MAS5 expression report provides statistics
for each chip that can be used for quality control purpos-
es. Included in this report are noise, background, the per-
cent of probe sets called present, the scaling factor
calculated by the absolute analysis algorithm and the ratio
of 3' to 5' signal for GAPDH and β-actin. These measures
were used to judge the quality and similarity of data from
the various RNA sample size groups.
MAS5 "absolute" and "comparison" expression analyses
were performed [11]. The RGU34A chip contains 8799
probe sets (series of probe pairs that query parts of the
same gene or EST) [7]. For each probe set, absolute analy-
sis generates a signal value (expression level), a detection
call of absent, present, or marginal, and a p-value associ-
ated with the detection call [11]. Comparison analysis ex-
amines 2 GeneChips® and indicates for each probe set
whether there is a significant difference in the signal be-
tween the two arrays. The output is a change call of in-
crease, marginal increase, decrease, marginal decrease or
no change, a p-value associated with the change call, and
the magnitude of the difference (as the signal log ratio, the
log2(log base 2) ratio of the signal from first chip to the
signal on the second or baseline chip). Comparisons were
made between the vitamin-deficient and normal diet ani-
mals in each sample size group using the normal diet sam-
ples as the baseline for each comparison. All possible
comparisons were made, this equaled 16 comparisons
each (4 × 4) for the 10 µg, 0.5 µg and 0.1 µg groups and 9
comparisons for the 2 µg samples. Comparisons were also
made between each of the 2 µg, 0.5 µg and 0.1 µg samples
and the 10 µg sample from the same animal, to look for
apparent differences in gene expression that are really due
to the differences in the amount of starting material and
sample processing. For these comparisons, the 10 µg sam-
ple was used as the baseline.
In addition, comparisons were made between the 10 µg
arrays within each treatment group to measure variability,
both between-animal and technical. This analysis was
done for the 0.5 µg group as well. The 0.1 µg arrays were
compared to the 0.5 µg arrays from the same animal, to
determine how well these two amplified samples corre-
sponded with one another.
Data from each RNA sample size group were exported and
each probe set analyzed in the following ways:
1. The number of GeneChips® on which a probe set was
detected within each of the treatment groups (normal vs.
deficient diet) was calculated. Each present call was as-
signed the value 1 and each marginal call assigned 0.51.
Only probe sets that are present in at least one-half of the
samples from one of the treatment groups (either normal
or deficient diet) were used for further analysis, we call
this the "detection filter". Note that we did not require the
probe set to be present in both treatment groups, just in
one. For this experiment, we required a score of at least 2
for the 10 µg, 0.1 µg and 0.5 µg groups (4 GeneChips® in
each treatment group) and 1.51 for the 2 µg and corre-
sponding 6-sample subset of the 10 µg groups (3
GeneChips® in each treatment group).
2. The sum of the calls from the comparison analyses was
calculated, using 1 for increase, 0.5 for marginal increase,
0 for no change, -0.5 for marginal decrease, and -1 for
decrease.
3. The mean, standard deviation and coefficient of varia-
tion of the signal for each probe set within each treatment
group (normal and deficient diet) were calculated.
4. Student's t-test for equal means with the assumption of
unequal variance [12] was calculated to test for significant
differences in signal (expression level) between the nor-
mal and vitamin deficient groups. This test was applied
separately to the signals and the log2 transformation of
the signals.
5. The Wilcoxon rank-sum non-parametric test for equal
means between normal and deficient diet groups [13] was
performed.
6. The log2 ratio (fold change) of the mean signals for nor-
mal vs. deficient diet groups was calculated:
log2 ratio = log2((mean of signal for normal) / (mean of
signal for deficient))
Changes within an RNA sample size group between nor-
mal and deficient diet groups were assessed as significant
if the probe set passed the "detection filter" (#1 above)
and the p-value was less than 0.01 for the t-test using
either the original signal or log transformed signal (#4
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Scatter plots comparing individual samples were created
using Microsoft Excel®. SAS (SAS Institute Inc., Cary, NC)
was used for univariate analysis of the signals for each
RNA sample size group.
Distance of target from 3' end
To calculate the distance of the target from the 3' end of
the interrogated sequence, the target sequence for each
probe set (supplied by Affymetrix; http://www.affyme-
trix.com was BLASTed [16,17] against the nr (non-redun-
dant) database at NCBI http://www.ncbi.nlm.nih.gov.
Using the first (best) alignment retumed, the distance of
the 5' end of the target sequence from the 3' end of the
mRNA or EST in the nr database was calculated (Figure 3).
A few of the alignments were rejected because the first
alignment was to a BAC sequence or to the wrong strand.
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